Business context and reporting period
The supplied filing is Aquinox Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2016; it does not identify Neurogene Inc. as the registrant. The company was a clinical-stage drug developer focused on inflammation and immuno-oncology. Its lead candidate, AQX-1125, was being developed for interstitial cystitis/bladder pain syndrome (IC/BPS).
Financial results and position
Amounts are in U.S. dollars; financial statement amounts below are in millions unless otherwise noted.
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.881 | $4.567 |
| General and administrative expense | $1.953 | $1.472 |
| Total operating expenses | $6.834 | $6.039 |
| Net loss | $6.711 | $6.412 |
| Net loss per share, basic and diluted | $0.39 | $0.60 |
| Cash used in operating activities | $5.872 | $6.300 |
At March 31, 2016, cash and cash equivalents were $35.7 million and short- and long-term investments totaled $71.6 million, for combined liquid resources of $107.3 million. Working capital was $63.8 million; total liabilities were $5.8 million, and accumulated deficit was $118.0 million. Cash and cash equivalents declined $3.8 million during the quarter. Investing activities provided $2.0 million, primarily reflecting investment maturities; financing activities provided no cash. The filing reports no product revenue and no profitability.
Changes versus the prior comparable period
- Net loss increased by about $0.3 million, while total operating expenses rose by $0.8 million. R&D expense increased 7% as clinical activity advanced toward Phase 3; G&A expense increased 33%, attributed mainly to personnel costs and opening a San Bruno office.
- Operating cash use decreased by $0.4 million, which management attributed primarily to the timing of payments for expenses incurred late in the quarter.
- Other income was $0.1 million versus other expense of $0.4 million in Q1 2015, reflecting higher interest income and lower foreign-exchange losses, among other items.
- Basic and diluted loss per share improved to $0.39 from $0.60, alongside a higher weighted-average share count: 17.2 million versus 10.7 million.
Outlook, commentary, and risks
- Management expected existing capital resources to fund operations for at least 12 months, while anticipating substantial future financing needs. It expected losses and R&D spending to continue and increase, particularly with AQX-1125 development.
- The company planned to initiate its first Phase 3 IC/BPS trial in 2016, subject to regulatory feedback, and anticipated two Phase 3 trials. FDA and EMA advice on proposed pivotal-trial designs was described as generally consistent. A tablet/capsule bioequivalence trial was completed in January 2016; future AQX-1125 trials were planned to use tablets.
- Results in IC/BPS were mixed: the Phase 2 Leadership 201 trial showed a positive trend on its primary endpoint and statistically significant changes on secondary endpoints, but did not achieve statistical significance on the primary endpoint. Earlier Phase 2 COPD and atopic dermatitis trials failed to demonstrate efficacy; no further development in those indications was planned. AQX-1125 was generally well tolerated in those trials.
- Key risks include unproven clinical efficacy and an unvalidated SHIP1 target, regulatory and trial execution uncertainty, dependence on third-party manufacturers and CROs, and the possibility that additional financing may not be available on acceptable terms. The company also cited animal toxicities, including gastrointestinal ulcerations and ocular-lens effects, as safety concerns to monitor; reported clinical side effects were most commonly mild gastrointestinal symptoms.
- Other notable disclosures: the company did not hedge foreign-currency exposure; a 100-basis-point rate increase was estimated to reduce investment fair value by $0.7 million. Management reported effective disclosure controls and no material change in internal control over financial reporting. The Chief Medical Officer gave notice of resignation effective August 5, 2016, unless earlier agreed.
Important facts for investors to verify
- Confirm the intended issuer: this text is Aquinox Pharmaceuticals’ filing, not a Neurogene Inc. filing.
- Track Phase 3 trial protocol, timing, enrollment, regulatory requirements, and whether the company’s cash runway remains consistent with management’s estimate.
- Review the full Leadership 201 primary-endpoint results and the evidence supporting the proposed Phase 3 design, given the primary endpoint did not reach statistical significance.
- Assess funding needs, potential dilution, and manufacturing capacity and backup-supplier plans as development advances.
- Monitor clinical safety findings, including whether animal toxicity signals emerge in human trials, and the transition in clinical-development leadership.